Business Context and Reporting Period
This Form 8-K is filed by Aquinox Pharmaceuticals, Inc. (not Neurogene Inc.) on May 13, 2014. The report announces the financial results for the first quarter ended March 31, 2014. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being located in the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of the Q1 2014 results.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. It serves solely as a notification that the press release containing this information has been issued.
Investor Verification Checklist
- Verify the correct registrant name is Aquinox Pharmaceuticals, Inc., not Neurogene Inc.
- Locate and review Exhibit 99.1 (the May 13, 2014 press release) for actual financial figures.
- Confirm the reporting period is the quarter ended March 31, 2014.
- Note that the information in this 8-K is furnished but not deemed "filed" under Section 18 of the Exchange Act.